Original communicationDetermination of prognosis in chronic disease, illustrated by systemic lupus erythematosus
References (11)
- Harvey, A. M., Shulman, L. E., Tumulty, P. A., Conley, C. L. and Schoenrich, E. H.: Systemic Lupus Erythematosus:...
- et al.
Calculation of Survival Rates for Cancer
- et al.
A Short Method for Constructing an Abridged Life Table
Am. J. Hyg.
(1939) Long-time Follow-up in Morbidity Studies: The Definition of the Group to be Followed
Human Biol.
(1950)The Errors of Sampling of the Survivorship Tables
Cited by (406)
The Giants of Rheumatology at Johns Hopkins: Lawrence E Shulman, MD, PhD and Mary Betty Stevens, MD
2024, Rheumatic Disease Clinics of North AmericaChallenges in systemic lupus erythematosus: From bench to bedside
2023, Translational Autoimmunity: Volume 6: Advances in Autoimmune Rheumatic DiseasesThe global burden of heterogeneity of lupus erythematosus interventional trials
2022, Journal of AutoimmunityCitation Excerpt :As a disease defined and classified mainly by clinical manifestations and the presence of autoantibodies, the exact pathogenetic mechanisms resulting in the inflammatory and immunological processes of LE remains elusive [1]. Due to advances in diagnosis and therapeutic strategies the 5-year survival rate of patients with systemic lupus erythematosus (SLE) has improved significantly to 95% in high-income countries and at 92% in low- and middle-income countries [2–4]. It appears that the incidence has increased worldwide [5,6] with the prevalence varying widely around the world from 0 to 241/100,000.
Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis
2021, International ImmunopharmacologyCitation Excerpt :Previous studies have shown that the mortality curve of SLE shows a bimodal pattern, with early death caused by SLE activity and complications, late death mainly due to cardiovascular disease (CVD), which accounts for more than one-third of SLE death causes [5]. Several studies have reported that compared with ordinary people, patients with SLE have a 2–10 times higher risk of developing CVD, including myocardial infarction, stroke, atherosclerosis, peripheral vascular diseases, etc. [1,6,7]. Scherlinger et al. 2020 has reported that the worldwide age-standardized mortality rate (ASMR) was 2.68 (95% CI: 2.62–2.75) deaths/millions of inhabitants, which has a strong heterogeneity across every country [8].
Disease development and outcome
2020, Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects